The use of stem cells may open a new era in the management of multiple sclerosis (MS ... Phase I/II controlled clinical trials in MS are warranted.

For now, stem cell therapy is most likely to help people who have active inflammation or frequent relapses. Research does not suggest it can repair serious damage or help those who already have a ...

A Phase 2 clinical trial testing obexelimab in adults with relapsing types of multiple sclerosis is now recruiting ...

ECTRIMS and EBMT said stem cell transplant can be considered for some with RRMS, such as those who are younger and have less ...

a research team discovered a type of T cell in humans that suppresses the immune system; they later found that these so-called regulatory T cells, when defective, are an ... Multiple Sclerosis ...

Parkinson’s and multiple sclerosis; cardiac conditions; and glaucoma, among other issues. None of these claims has been supported by scientific research. The only stem cell products the FDA has ...

Ncardia’s iPSC-derived microglia may aid ALS research and help to screen new therapies that target inflammation in ALS.

The global cell separation market size was valued at USD 9.74 billion in 2024 and is projected to reach from USD 10.69 ...

While there’s no cure for multiple sclerosis ... and reduce symptoms. Stem cells have shown some promise in treating the neural damage that MS causes. Research on stem cells in MS has included ...

"With the global stem cell market expanding, we see an opportunity to make these treatments more accessible in the U.S.," ...

For years, the Food and Drug Administration has taken up arms against clinics hawking unproven and ineffective stem cell treatments ... Parkinson’s, multiple sclerosis and even erectile dysfunction.